Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · April 01, 2015

Irinotecan Plus Cisplatin vs Irinotecan Alone in Patients With Advanced Gastric Cancer Refractory to S-1 Monotherapy

European Journal of Cancer

 

Additional Info

European Journal of Cancer
Randomised Phase III Trial of Second-Line Irinotecan Plus Cisplatin Versus Irinotecan Alone in Patients With Advanced Gastric Cancer Refractory to S-1 Monotherapy: TRICS Trial
Eur. J. Cancer 2015 Mar 19;[EPub Ahead of Print], K Nishikawa, K Fujitani, H Inagaki, Y Akamaru, S Tokunaga, M Takagi, S Tamura, N Sugimoto, T Shigematsu, T Yoshikawa, T Ishiguro, M Nakamura, S Morita, Y Miyashita, A Tsuburaya, J Sakamoto, T Tsujinaka

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading